KISSEI PHARMACEUTICAL CO.,LTD. [4547.T]
TOKYO, May 01 (Pulse News Wire) – Kissei Pharmaceutical CO.,LTD. (4547.T) announced today that it has entered into a sub-license agreement with Orient EuroPharma Co., Ltd.
(OEP) for the development and commercialization rights of acute myeloid leukemia treatment drug Oraltansine in Taiwan. Under the agreement, OEP will handle the development and commercialization of Oraltansine in Taiwan, while Kissei will supply the drug and receive upfront payments along with milestone payments based on progress in Taiwan. Oraltansine was originally licensed from Rigel Pharmaceuticals, Inc. in 2024 for exclusive development and sales rights in Japan, South Korea, and Taiwan. It inhibits IDH1 mutations, which hinder normal cell differentiation and promote tumor transformation.
The drug received FDA approval in December 2022 for relapsed/refractory AML patients with IDH1 mutations. Kissei aims to collaborate with partners to advance Oraltansine's development globally and bring the treatment to patients suffering from relapsed/refractory AML as soon as possible. Details of the integrated forecast for the fiscal year ending March 2027 will be disclosed during the earnings release scheduled for May 11, 2026. OEP, founded in 1982, specializes in oncology drugs and biologics, expanding its portfolio through international partnerships. Since signing a technology licensing deal for Gufast in 2005, OEP has maintained a long-term partnership with Kissei.
🟢 Confidence: High AI-translated content.